Cytogenetic risk group and cytogenetic response predict outcome of patients  with poor-risk mds and secondary aml treated with intensive chemotherapy and  stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK,  HOVON and GIMEMA leukemia groups

de Witte, T; Hagemeijer-Hausman, Anne; Suciu, S; Delforge, Michel; Jotterand-bellomo, M; Tigaud, I; Belhabri, A; Aul, C; Avaido, M; Selleslag, D; Schouten, H; Ferrant, A; Amadori, S; Muus, P; Anak, O; Beeldens, F; Janden, J; Hellstrom-Lindberg, E; Gratwohl, A; Willemze, R

Blood

Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups

Author:

de Witte, T

Hagemeijer-Hausman, Anne ; Suciu, S ; Delforge, Michel ; Jotterand-bellomo, M ; Tigaud, I ; Belhabri, A ; Aul, C ; Avaido, M ; Selleslag, D ; Schouten, H ; Ferrant, A ; Amadori, S ; Muus, P ; Anak, O ; Beeldens, F ; Janden, J ; Hellstrom-Lindberg, E ; Gratwohl, A ; Willemze, R

Keywords:

1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine, Immunology, 3101 Biochemistry and cell biology, 3201 Cardiovascular medicine and haematology, 3213 Paediatrics

Blood Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups

Author:

Keywords:

Blood

Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups